title: [Simultaneous infusion of vinorelbin and taxol as first-line chemotherapy in metastasized breast cancer].
abstract: OBJECTIVE
  To evaluate the activity and toxicity of simultaneous infusion of vinorelbine (VNB) and paclitaxel (T) as first line chemotherapy in advanced breast cancer patients (pts).
  
  
  METHODS
  33 pts with histologically proven advanced breast cancer were treated with VNB 25 mg/m2 and T 150 mg/m2, both drugs given by i.v. infusion over 3 hours, with cycles repeated every 3 weeks. Granulocyte-colony-stimulating factor (G-CSF), 300 micrograms subcutaneously, was given on days 7 to 12 of each cycle in the first 10 patients.
  
  
  RESULTS
  From October 1995 to July 1996, 33 untreated pts entered the study. Characteristics of the pts were the following: median age 53 years (29-71); median WHO performance status 1 (0-3); pre/postmenopausal 8/25; prior adjuvant chemotherapy 16; prior radiotherapy 8; dominant disease sites: soft tissue in 6; bone in 7, viscera in 19; number of metastatic sites: 1 in 18, 2 in 9, 3 in 6 pts. In 31 evaluable pts we observed: 1 CR (3%) and 14 PR (45%), for an overall response rate of 48%. Median time to response was 2 months; median time to progression and median survival were 7 and 22+ months, respectively. Median number of cycles was 6. Myelosuppression was the dose-limiting toxicity, with G 4 neutropenia occurring in 22% of the pts and neutropenic fever in 6% of the pts. Other toxicities were generally mild with nausea in 52% of the pts; mucositis in 15%; constipation in 12%; peripheral neuropathy in 46.5%. Alopecia was universal.
  
  
  CONCLUSIONS
  Simultaneous infusion of VNB and T is well tolerated and active in untreated patients with advanced breast cancer. Median survival (22+ months) is similar to that reported with anthracycline-containing regimens, although response rate appears to be lower. It is likely that higher response rates may be achieved with a higher dose-intensity.
authors.affiliation: Divisione di Oncologia Medica II, Istituto Regina Elena, Roma, Italia.
authors.forename: P
authors.initials: P
authors.lastname: Vici
authors.forename: F
authors.initials: F
authors.lastname: Conti
authors.forename: A
authors.initials: A
authors.lastname: Amodio
authors.forename: F
authors.initials: F
authors.lastname: Belli
authors.forename: M
authors.initials: M
authors.lastname: Della Giulia
authors.forename: S
authors.initials: S
authors.lastname: Mariotti
authors.forename: T
authors.initials: T
authors.lastname: Gionfra
authors.forename: M
authors.initials: M
authors.lastname: Lopez
mesh_terms: D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000627:therapeutic use*; D010166:Palliative Care; D014747:Vinblastine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077235:Vinorelbine
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D014747:Vinblastine; D017239:Paclitaxel; D000077235:Vinorelbine
vernacular_title: Infusione simultanea di vinorelbina e taxolo come chemioterapia di prima linea nel trattamento del carcinoma mammario metastatizzato.